Current status of ischemic stroke treatment: From thrombolysis to potential regenerative medicine

Mason Daniel Hurd; Isha Goel; Yasuyuki Sakai; Yuji Teramura

doi:10.1016/j.reth.2021.09.009

Current status of ischemic stroke treatment: From thrombolysis to potential regenerative medicine

Regen Ther. 2021 Oct 12:18:408-417. doi: 10.1016/j.reth.2021.09.009. eCollection 2021 Dec.

Authors

Mason Daniel Hurd¹, Isha Goel¹, Yasuyuki Sakai², Yuji Teramura^{3

4}

Affiliations

¹ Department of Bioengineering, School of Engineering, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8656, Japan.
² Department of Chemical System Engineering, School of Engineering, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8656, Japan.
³ Cellular and Molecular Biotechnology Research Institute (CMB), National Institute of Advanced Industrial Science and Technology (AIST), Tsukuba Central fifth, 1-1-1 Higashi, Tsukuba, Ibaraki, 305-8565, Japan.
⁴ Department of Immunology, Genetics and Pathology (IGP), Uppsala University, Dag Hammarskjölds väg 20, SE-751 85, Uppsala, Sweden.

Abstract

Ischemic stroke is a major cause of death and disability worldwide and is expected to increase in the future with the aging population. Currently, there are no clinically available treatments for damage sustained during an ischemic stroke, but much research is being conducted in this area. In this review, we will introduce current ischemic stroke treatments along with their limitations, as well as research on potential short and long-term future treatments. There are advantages and disadvantages in these potential treatments, but our understanding of these methods and their effectiveness in clinical trials are improving. We are confident that some future treatments introduced in this review will become commonly used in clinical settings in the future.

Keywords: Exosomes; Ischemic stroke; Regenerative medicine; Stem cells; Treatments.

Publication types

Review